News

Multiple Sclerosis

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

1600 1067 Julien Ferrari, PharmD, PhD

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients. You can find the original press…

read more

​A new milestone in acute stroke treatment

6000 4000 Camilla Norrmén, PhD

Two recent studies have prompted the American Heart Association (AHA) to change their guidelines on early stroke management, extending the window of emergency stroke treatment up to 24 hours. Two randomized…

read more

From undercooked meat to neuralgic amyotrophy

1920 1080 Michael Furrer, PhD

We have talked to Dr Paolo Ripellino from the Ospedale Civico di Lugano (EOC), Switzerland, about his research on neurological complications related to hepatitis E infection. Dr Ripellino has recently…

read more

​80-year track record of neurosurgical success

1600 1605 Jared Ou-Young, MSc

The UniversitätsSpital Zürich (USZ) reaches a milestone anniversary in 2017. From humble beginnings to now being one of the top-teaching institutions in Europe, USZ continues to lead and pioneer innovations in vascular,…

read more

Impressive results for a new vaccine

1600 1076 Camilla Norrmén, PhD

Experts are enthusiastic about a new shingles vaccine that received FDA approval last month. Shingrix is significantly more effective than the only currently available shingles vaccine and provides considerably longer…

read more

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

150 150 Lutz Achtnichts, MD

I had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the long-term treatment effect of teriflunomide…

read more

ECTRIMS-ACTRIMS: A conversation with Dr Patricia Mulero

150 150 Lutz Achtnichts, MD

At ECTRIMS-ACTRIMS in Paris, France, I had the chance to sit down with Dr Patricia Mulero to discuss FLOODLIGHT: a prospective pilot study that has been exploring the feasibility of…

read more

ECTRIMS-ACTRIMS: A conversation with Dr Tanuja Chitnis

150 150 Lutz Achtnichts, MD

Children and adolescents living with MS face physical and cognitive disability that can severely limit their ability to perform daily activities, such as attending school. During the recent ECTRIMS-ACTRIMS meeting…

read more

ECTRIMS-ACTRIMS: Updates to safety of ocrelizumab in pregnancy still “ongoing” after new analysis

898 599 Peter Stevenson, PhD

An update on pregnancy outcomes following ocrelizumab (OCR) treatment in patients with multiple sclerosis (MS) and other autoimmune diseases was delivered at this year’s joint ECTRIMS-ACTRIMS meeting, held 25-28 October…

read more

ECTRIMS-ACTRIMS: Teriflunomide for multiple sclerosis: is it safe in pregnancy?

898 506 Peter Stevenson, PhD

Friday’s programme at the ECTRIMS-ACTRIMS meeting in Paris played host to an exploration of pregnancy outcomes in multiple sclerosis (MS) patients treated with teriflunomide –  a once-daily oral immunomodulator approved…

read more
Brainwork is supported by unrestricted grants from: